Posts by VIVA! Communications
Return to lock-down sees Victorian pharmacists step up for community members
With parts of Victoria entering Stage 3 restrictions last night (8 July) pharmacists on the frontline are stepping up to provide essential services to local residents facing six-week stay-at-home orders. With over 932 active COVID-19 cases in Victoria, Victorian pharmacists in the greater Melbourne and Mitchel Shire are responding to the crisis swiftly to ensure…
Read MoreMental health of Australians with asthma impacted by COVID-19
Early findings from a recent survey by Asthma Australia reveal 44 per cent of Australians with asthma experienced new or increasing symptoms of anxiety or depression during the COVID-19 pandemic, and one in four say the stress has been triggering their asthma. The findings, published in a report submitted to a Senate enquiry into the…
Read MoreNew report reveals the impact of MedTech collaborations on COVID
A series of reports released today by MTPConnect, an independent, industry-led organisation, highlight the key role the MedTech sector played in the COVID-19 pandemic response. The reports, welcomed by the Medical Technology Association of Australia (MTAA), reveal how the MedTech, biotechnology and pharmaceutical sector was impacted by COVID-19 at local and multinational levels, as well…
Read MoreImpact on COVID-19 on cancer diagnosis, treatment & patient mental health
Insights from Professor Stephen Clarke OAM This week, VIVA! Communications’ Principal, Kirsten Bruce spoke with award-winning Medical Oncologist, Pharmacologist and Translational Researcher, Professor Stephen Clarke OAM, Sydney, about clinical practice during COVID-19, the impact of the virus on cancer diagnosis and treatment, and how cancer patients are faring from a mental health perspective. Although the…
Read MoreNew combination therapy now reimbursed for Aussies living with incurable blood cancer
Yesterday, VIVA! partnered with Celgene, a Bristol-Myers Squibb company and Myeloma Australia to announce the listing of REVLIMID® (lenalidomide) in combination with bortezomib (Velcade) and dexamethasone (RVd) on the Pharmaceutical Benefits Scheme (PBS). Australians living with the incurable blood cancer, multiple myeloma now have access to this new treatment option. The three drug regimen will…
Read More